Epigenomics AG (LTS:0QXH) Valuation Rank

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0QXH Epigenomics AG LTS:0QXH
18 GF Score
Price €0.88
GF Value €0.08
! 3 Warning Signs
View Full Analysis

What is Epigenomics AG Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.

Epigenomics AG Valuation Rank Related Terms

LTS:0QXH
18GF Score
Epigenomics AG LTS:0QXH
Valuation Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Epigenomics AG (LTS:0QXH) Overvalued in 2026?

Based on GuruFocus' analysis, Epigenomics AG stock appears to be overvalued. The current stock price of €0.88 is trading 1002.5% above its estimated GF Value™ of €0.08.

Key valuation signals for LTS:0QXH:

  • Valuation Rank:
  • GF Value™: €0.08 vs. price of €0.88 (1002.5% above fair value)
  • GF Score™: 18/100 with 3 warning signs

No single metric tells the full story. See the LTS:0QXH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Epigenomics AG Business Description

Other Exchanges ECX:Germany
Address Ziegelhauser Landstrabe 3, Heidelberg, BW, DEU, 69120
Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.
18GF Score

Get the complete analysis for LTS:0QXH

Valuation Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.88
Price
€0.08
GF Value